Upcoming Dividend • May 12
Upcoming dividend of HK$0.16 per share Eligible shareholders must have bought the stock before 19 May 2026. Payment date: 12 June 2026. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Hong Kong dividend payers (6.7%). Higher than average of industry peers (1.6%). Major Estimate Revision • Apr 07
Consensus revenue estimates fall by 12% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥856.0m to CN¥751.0m. EPS estimate fell from CN¥0.488 to CN¥0.433 per share. Net income forecast to grow 0.6% next year vs 8.4% growth forecast for Healthcare Services industry in Hong Kong. Consensus price target down from HK$16.03 to HK$14.17. Share price was steady at HK$8.61 over the past week. Declared Dividend • Mar 28
Final dividend of HK$0.16 announced Shareholders will receive a dividend of HK$0.16. Ex-date: 19th May 2026 Payment date: 12th June 2026 Dividend yield will be 3.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is covered by earnings (41% earnings payout ratio) but not covered by cash flows (145% cash payout ratio). The dividend has increased by an average of 97% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 27
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥0.46 (up from CN¥0.43 in FY 2024). Revenue: CN¥642.2m (up 15% from FY 2024). Net income: CN¥334.3m (up 6.1% from FY 2024). Profit margin: 52% (down from 56% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) exceeded analyst estimates by 3.6%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Healthcare Services industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Mar 26
Medlive Technology Co., Ltd., Annual General Meeting, May 15, 2026 Medlive Technology Co., Ltd., Annual General Meeting, May 15, 2026. Announcement • Mar 16
Medlive Technology Co., Ltd. to Report Fiscal Year 2025 Results on Mar 26, 2026 Medlive Technology Co., Ltd. announced that they will report fiscal year 2025 results on Mar 26, 2026 Buy Or Sell Opportunity • Feb 05
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 3.2% to HK$10.06. The fair value is estimated to be HK$8.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 42%. Revenue is forecast to grow by 58% in 2 years. Earnings are forecast to grow by 20% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$10.22, the stock trades at a forward P/E ratio of 20x. Average trailing P/E is 21x in the Healthcare Services industry in Asia. Total loss to shareholders of 1.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.18 per share. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to HK$11.86, the stock trades at a forward P/E ratio of 23x. Average trailing P/E is 22x in the Healthcare Services industry in Asia. Total returns to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.09 per share. Buy Or Sell Opportunity • Jan 02
Now 20% overvalued Over the last 90 days, the stock has fallen 23% to HK$9.83. The fair value is estimated to be HK$8.16, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 42%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 20% in the next 2 years. Buy Or Sell Opportunity • Dec 11
Now 21% overvalued Over the last 90 days, the stock has fallen 29% to HK$9.79. The fair value is estimated to be HK$8.07, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 42%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 20% in the next 2 years. Buy Or Sell Opportunity • Nov 24
Now 21% overvalued Over the last 90 days, the stock has fallen 32% to HK$9.79. The fair value is estimated to be HK$8.10, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 42%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 20% in the next 2 years. New Risk • Oct 17
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 144% Dividend yield: 2.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (144% cash payout ratio). Significant insider selling over the past 3 months (HK$3.6m sold). Upcoming Dividend • Aug 29
Upcoming dividend of HK$0.13 per share Eligible shareholders must have bought the stock before 05 September 2025. Payment date: 25 September 2025. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 2.0%. Lower than top quartile of Hong Kong dividend payers (6.6%). Higher than average of industry peers (1.0%). Reported Earnings • Aug 27
First half 2025 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1H 2024) First half 2025 results: EPS: CN¥0.21 (up from CN¥0.20 in 1H 2024). Revenue: CN¥312.0m (up 28% from 1H 2024). Net income: CN¥155.3m (up 5.9% from 1H 2024). Profit margin: 50% (down from 60% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Healthcare Services industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Aug 09
Medlive Technology Co., Ltd. to Report First Half, 2025 Results on Aug 25, 2025 Medlive Technology Co., Ltd. announced that they will report first half, 2025 results on Aug 25, 2025 Recent Insider Transactions • Jul 19
Board Member recently sold HK$3.6m worth of stock On the 18th of July, Lijun Tian sold around 240k shares on-market at roughly HK$15.02 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of HK$6.8m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$13.80, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 24x in the Healthcare Services industry in Asia. Total returns to shareholders of 67% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.04 per share. Upcoming Dividend • May 06
Upcoming dividend of HK$0.15 per share Eligible shareholders must have bought the stock before 12 May 2025. Payment date: 06 June 2025. Payout ratio is a comfortable 59% but the company is paying out more than the cash it is generating. Trailing yield: 2.3%. Lower than top quartile of Hong Kong dividend payers (7.8%). Higher than average of industry peers (1.1%). New Risk • Apr 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to HK$9.71, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 18x in the Healthcare Services industry in Asia. Total returns to shareholders of 25% over the past three years. Major Estimate Revision • Mar 31
Consensus EPS estimates increase by 23% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from CN¥698.7m to CN¥725.4m. EPS estimate increased from CN¥0.365 to CN¥0.449 per share. Net income forecast to grow 8.5% next year vs 22% growth forecast for Healthcare Services industry in Hong Kong. Consensus price target up from HK$11.00 to HK$16.25. Share price was steady at HK$13.10 over the past week. Reported Earnings • Mar 25
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: CN¥0.43 (up from CN¥0.34 in FY 2023). Revenue: CN¥558.5m (up 36% from FY 2023). Net income: CN¥315.1m (up 30% from FY 2023). Profit margin: 56% (down from 59% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.8%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Announcement • Mar 07
Medlive Technology Co., Ltd. to Report Fiscal Year 2024 Results on Mar 24, 2025 Medlive Technology Co., Ltd. announced that they will report fiscal year 2024 results on Mar 24, 2025 Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to HK$15.82, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 19x in the Healthcare Services industry in Asia. Total returns to shareholders of 85% over the past three years. New Risk • Feb 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (43% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change). Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to HK$10.20, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 21x in the Healthcare Services industry in Asia. Total loss to shareholders of 5.4% over the past three years. Upcoming Dividend • Oct 15
Upcoming dividend of HK$0.13 per share Eligible shareholders must have bought the stock before 22 October 2024. Payment date: 18 November 2024. Payout ratio is a comfortable 61% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (1.0%). Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to HK$9.88, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 1x in the Healthcare Services industry in Hong Kong. Total loss to shareholders of 72% over the past three years. Reported Earnings • Sep 27
First half 2024 earnings: EPS and revenues exceed analyst expectations First half 2024 results: EPS: CN¥0.20 (up from CN¥0.14 in 1H 2023). Revenue: CN¥243.4m (up 40% from 1H 2023). Net income: CN¥146.7m (up 49% from 1H 2023). Profit margin: 60% (up from 57% in 1H 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Major Estimate Revision • Sep 03
Consensus EPS estimates increase by 34% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥516.8m to CN¥537.4m. EPS estimate increased from CN¥0.284 to CN¥0.38 per share. Net income forecast to grow 1.8% next year vs 1.8% growth forecast for Healthcare Services industry in Hong Kong. Consensus price target up from HK$10.27 to HK$11.09. Share price rose 3.1% to HK$7.91 over the past week. Reported Earnings • Aug 29
First half 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 1H 2023) First half 2024 results: EPS: CN¥0.20 (up from CN¥0.14 in 1H 2023). Revenue: CN¥243.4m (up 40% from 1H 2023). Net income: CN¥146.7m (up 49% from 1H 2023). Profit margin: 60% (up from 57% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Announcement • Aug 27
Medlive Technology Co., Ltd. Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 18 November 2024 Medlive Technology Co., Ltd. announced Interim Dividend of RMB 0.1205 per share (HKD 0.132 per share) for the Six Months Ended 30 June 2024. Ex-dividend date is 22 October 2024. Record date is 28 October 2024. Payment date is 18 November 2024. Announcement • Aug 09
Medlive Technology Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024 Medlive Technology Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024 Announcement • Jul 15
Medlive Technology Co., Ltd. Announces Company Secretary Changes Medlive Technology Co., Ltd. announced that the Stock Exchange has confirmed that Ms. Ms. Yang Yanling is qualified to act as the company secretary of the Company under Rule 3.28 of the Listing Rules. Accordingly, Ms. Yang will act as the sole company secretary and an Authorised Representative of the Company with effect from 15 July 2024. Ms. Cheuk Ting has resigned as a joint company secretary and an Authorised Representative of the Company with effect from 15 July 2024. Ms. Chu will remain as the Process Agent. Ms. Chu has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange. Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$8.15, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Healthcare Services industry in Asia. Total loss to shareholders of 72% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$4.90 per share. Upcoming Dividend • May 21
Upcoming dividend of HK$0.14 per share Eligible shareholders must have bought the stock before 28 May 2024. Payment date: 24 June 2024. Payout ratio is a comfortable 69% but the company is paying out more than the cash it is generating. Trailing yield: 3.3%. Lower than top quartile of Hong Kong dividend payers (7.4%). Higher than average of industry peers (1.1%). Reported Earnings • May 01
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CN¥0.34 (up from CN¥0.16 in FY 2022). Revenue: CN¥412.0m (up 31% from FY 2022). Net income: CN¥242.3m (up 107% from FY 2022). Profit margin: 59% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.1%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Asia. Major Estimate Revision • Apr 01
Consensus EPS estimates increase by 36% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥503.5m to CN¥516.8m. EPS estimate increased from CN¥0.209 to CN¥0.284 per share. Net income forecast to shrink 0.8% next year vs 15% growth forecast for Healthcare Services industry in Hong Kong . Consensus price target broadly unchanged at HK$10.09. Share price was steady at HK$7.55 over the past week. Announcement • Mar 26
Medlive Technology Co., Ltd., Annual General Meeting, May 24, 2024 Medlive Technology Co., Ltd., Annual General Meeting, May 24, 2024. Reported Earnings • Mar 26
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CN¥0.34 (up from CN¥0.16 in FY 2022). Revenue: CN¥412.0m (up 31% from FY 2022). Net income: CN¥242.3m (up 107% from FY 2022). Profit margin: 59% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.1%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Asia. Buy Or Sell Opportunity • Mar 21
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 8.1% to HK$7.72. The fair value is estimated to be HK$6.23, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last year. Earnings per share has grown by 288%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 1.6% per annum over the same time period. Announcement • Mar 14
Medlive Technology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 25, 2024 Medlive Technology Co., Ltd. announced that they will report fiscal year 2023 results on Mar 25, 2024 Buy Or Sell Opportunity • Feb 27
Now 21% overvalued Over the last 90 days, the stock has fallen 19% to HK$7.58. The fair value is estimated to be HK$6.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last year. Earnings per share has grown by 288%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 6.0% per annum over the same time period. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to HK$8.48, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 29x in the Healthcare Services industry in Asia. Total returns to shareholders of 1.8% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$6.59 per share. Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$8.10, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 28x in the Healthcare Services industry in Asia. Total loss to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$6.59 per share. Valuation Update With 7 Day Price Move • Nov 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$9.40, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 29x in the Healthcare Services industry in Asia. Total returns to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$6.55 per share. Upcoming Dividend • Oct 31
Upcoming dividend of HK$0.12 per share at 1.5% yield Eligible shareholders must have bought the stock before 07 November 2023. Payment date: 04 December 2023. Payout ratio is a comfortable 65% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Hong Kong dividend payers (8.3%). Higher than average of industry peers (0.8%). New Risk • Sep 23
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 71% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 31
First half 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.038 in 1H 2022) First half 2023 results: EPS: CN¥0.14 (up from CN¥0.038 in 1H 2022). Revenue: CN¥173.5m (up 32% from 1H 2022). Net income: CN¥98.7m (up 266% from 1H 2022). Profit margin: 57% (up from 20% in 1H 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Healthcare Services industry in Hong Kong. Announcement • Aug 30
Medlive Technology Co., Ltd. Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 04 December 2023 Medlive Technology Co., Ltd. announced interim dividend of RMB 0.1067 per share for the Six Months Ended 30 June 2023. Default currency and amount in which the dividend will be paid: HKD 0.1165 per share. Ex-dividend is date 07 November 2023, Record date is 13 November 2023 and Payment date is 04 December 2023. Announcement • Aug 18
Medlive Technology Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Medlive Technology Co., Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Announcement • Jun 13
Medlive Technology Co., Ltd. Announces Executive Changes The board of directors of Medlive Technology Co., Ltd. announces that Ms. Szeto Kar Yee Cynthia ("Ms. Szeto") has resigned from her positions as the joint company secretary of the Company (the "Joint Company Secretary"), due to other work arrangements, with effect from 12 June 2023. The Board is also announce that Ms. Chu Cheuk Ting ("Ms. Chu") has been appointed by the Company as the Joint Company Secretary, the Authorized Representative and the Process Agent in place of Ms. Szeto, with effect from 12 June 2023. Ms. Yang Yanling ("Ms. Yang") will continue to serve as the other Joint Company Secretary of the Company. Ms. Chu currently serves as a manager of the listing services department of TMF Hong Kong Limited and is responsible for provision of corporate secretarial and compliance services to listed company clients. Ms. Chu has accumulated over 12 years of experience in the professional company secretarial field, and she is an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Ms. Yang was appointed as a joint company secretary of the Company on 4 March 2021.Ms. Yang joined the Group in March 2018 and currently serves as a human resources manager of the Group and is in charge of the overall management of the human resources department and assists in the management of other operation departments including medical, design and creative departments. Before joining the Group, Ms. Yang served as human resources specialist in a few domestic companies. Ms. Yang obtained a bachelor's degree in agriculture from Hebei North University in June 2013. Upcoming Dividend • Jun 06
Upcoming dividend of HK$0.075 per share at 0.9% yield Eligible shareholders must have bought the stock before 13 June 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (0.5%). Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$8.60, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 33x in the Healthcare Services industry in Asia. Total returns to shareholders of 3.4% over the past year. Reported Earnings • Mar 24
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: CN¥0.16 (up from CN¥0.066 in FY 2021). Revenue: CN¥314.1m (up 10% from FY 2021). Net income: CN¥117.3m (up 189% from FY 2021). Profit margin: 37% (up from 14% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Healthcare Services industry in Asia. Recent Insider Transactions • Dec 14
Board Member recently sold HK$600k worth of stock On the 7th of December, Lijun Tian sold around 50k shares on-market at roughly HK$12.00 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought HK$2.1m more than they sold in the last 12 months. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Richard L. Yeh was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Sep 01
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from CN¥0.18 to CN¥0.16 per share. Revenue forecast steady at CN¥342.5m. Net income forecast to grow 159% next year vs 33% growth forecast for Healthcare Services industry in Hong Kong. Consensus price target broadly unchanged at HK$14.86. Share price fell 2.3% to HK$12.56 over the past week. Reported Earnings • Aug 27
First half 2022 earnings released: EPS: CN¥0.038 (vs CN¥0.037 in 1H 2021) First half 2022 results: EPS: CN¥0.038 (up from CN¥0.037 in 1H 2021). Revenue: CN¥132.0m (up 1.0% from 1H 2021). Net income: CN¥27.0m (up 37% from 1H 2021). Profit margin: 20% (up from 15% in 1H 2021). Over the next year, revenue is forecast to grow 41%, compared to a 18% growth forecast for the Healthcare Services industry in Hong Kong. Announcement • Aug 13
Medlive Technology Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022 Medlive Technology Co., Ltd. announced that they will report first half, 2022 results on Aug 25, 2022 Reported Earnings • Apr 30
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.066 (down from CN¥0.16 in FY 2020). Revenue: CN¥284.4m (up 33% from FY 2020). Net income: CN¥40.6m (down 52% from FY 2020). Profit margin: 14% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 95%. Over the next year, revenue is forecast to grow 27%, compared to a 18% growth forecast for the industry in Hong Kong. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-executive Director Zhuolin Li was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Apr 03
Chairwoman recently bought HK$1.4m worth of stock On the 29th of March, Liping Tian bought around 195k shares on-market at roughly HK$7.07 per share. This was the largest purchase by an insider in the last 3 months. Liping has been a buyer over the last 12 months, purchasing a net total of HK$2.7m worth in shares. Major Estimate Revision • Mar 31
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from CN¥574.8m to CN¥514.2m. EPS estimate increased from CN¥2.15 to CN¥4.02 per share. Net income forecast to grow 227% next year vs 27% growth forecast for Healthcare Services industry in Hong Kong. Consensus price target down from HK$32.25 to HK$30.76. Share price fell 27% to HK$7.90 over the past week. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment deteriorated over the past week After last week's 21% share price decline to HK$9.10, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 33x in the Healthcare Services industry in Asia. Simply Wall St's valuation model estimates the intrinsic value at HK$7.40 per share. 
